Find a Clinical Trial

Showing 131 - 140 of 169 Trials

A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT06860594

Population:

Adult

Phase:

I

Researchers recently found that triapine can make radiation therapy work better against glioblastoma cells and in mice with glioblastoma. Tumors did not grow for a longer time after treatment with triapine along with radiation compared to radiation alone. Triapine has also been tested in people with other types of cancers and has been found to be safe. This study is being done to answer the following question: What is the highest dose of triapine that can be safely and tolerably taken in combination with radiation therapy in patients with recurrent glioblastoma or astrocytoma? We are doing...
A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients with IDH1 Mutation-Positive Malignancies Being

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT07486713

Population:

Adult

Phase:

I

This is a research study that involves studying olutasidenib in participants whose tumors have a specific change in a gene called IDH1 (known as IDH1m+). This gene change can affect how the tumor grows and responds to treatment. The purpose of the study is to gather additional information about how the study drug, olutasidenib, behaves in the body and how it interacts with other medications, specifically with caffeine, bupropion, pioglitazone, losartan, lansoprazole, triazolam, and pravastatin. The study will also assess the safety and tolerability of these drugs when taken together. This...
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07312903

Population:

Adult

Phase:

I

The purpose of this study is to evaluate if the study drug is safe and well-tolerated. This research study is a first-in-human study. This means that if you participate in this study, you will be one of the first people to receive DPTX3186. The study drug, DPTX3186, is an investigational drug which means it is not approved by any country, including in the United States by the Food and Drug Administration (FDA). DPTX3186 is a small drug-like compound created to target special areas inside cells called condensates. Condensates are compartments inside cells that don't have membranes. They...
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T- Cells Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA™ )

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT05473910

Population:

Adult

Phase:

I

The study involves research of two study drugs (TSC 100 and TSC 101), given in combination with the standard of care (SOC). The purpose of the study is to see if TSC 100 and TSC 101 are safe and effective in treating your blood cancer. The study also is measuring the effect of these study drugs on your immune system (immunogenicity of study drugs). TSC 100 and TSC-101 are experimental new study drugs that have not yet been approved by the US Food and Drug Administration (FDA) or regulatory authorities in any other countries. This is a first-in-human study, which means that these study drugs...
An open-label, Phase 1b study to evaluate the safety andtolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma or astrocytoma

Principal Investigator:

Maria Diaz Ordonez, MD

Contact Number:

212-342-5162

NCT Number:

NCT05879367

Population:

Adult

Phase:

I

The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.This study will also measure levels of eflornithine in patients following dosing, and it will evaluate how effective eflornithine is as a treatment of GBM when combined with temozolomide. Eflornithine is an experimental drug, which means that it...
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06561685

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...
A MULTICENTER, OPEN-LABEL PHASE 1/1B/PHASE 2DOSE-FINDING, SAFETY, AND PHARMACOKINETICSTUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYLAURISTATIN E (MMAE) ANTIBODY DRUGCONJUGATE, IN ADVANCED REFRACTORYSOLID TUMORS

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06014658

Population:

Adult

Phase:

I

The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...
A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06625775

Population:

Adult

Phase:

I

The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab inPatients With Advanced or Metastatic Hepatocellular Carcinoma

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06600321

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: • The frequency and severity of side effects (to determine if the drug is safe) • Whether ALN-BCAT may make tumors smaller • How ALN-BCAT may affect the genes and proteins in your cancer cells • How your body processes ALN-BCAT Are you Eligible? (Inclusion Criteria) Age 18 years or older - Patient able to understand and willing and able to comply with...
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06917079

Population:

Adult

Phase:

I

The purpose of this study is to find the best dose of the study drug, BBO-11818, when used alone (single therapy) and in combination with other standard of care treatments, and to see what effects, good or bad, the study drug has on participants. While the standard of care treatments, pembrolizumab, pemetrexed, cisplatin, carboplatin, and cetuximab are FDA-approved individually, the combination of BBO-11818 with these treatments is considered experimental. The study drug, BBO-11818, has not been approved by the U.S. Food and Drug Administration (FDA). This is the first time that BBO- 11818...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages